Floatz logo

Piracetam

Postpoliomyelitis Syndrome

Small moleculePhase 3Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Postpoliomyelitis Syndrome cohort.

Asset / SponsorPhaseRating
L-Carnitine
Phase 3B
Modafinil
National Institute of Neurological Disorders and Stroke (NINDS)
Phase 3B
Xepol
Calliditas Therapeutics AB
N/ANR

Same molecule, other indications

Piracetam is also rated in:

middle cerebral artery infarctionDormant
CCC
Indicative ·
48 / 100
View asset →
physiological malfunction arising from mental factorDormant
CC
Indicative ·
45 / 100
View asset →
dementiaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →